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Abstract
Painful peripheral neuropathy belongs to major side-effects limiting cancer chemotherapy. Paclitaxel, widely used to
treat several cancers, induces neurological symptoms including burning pain, allodynia, hyperalgesia and numbness.
Therefore, identification of drugs that may effectively counteract paclitaxel-induced neuropathic symptoms is crucial.
Here, we combined histopathological, neurochemical, behavioral and electrophysiological methods to investigate the
natural neurosteroid 3α-androstanediol (3α-DIOL) ability to counteract paclitaxel-evoked peripheral nerve tissue
damages and neurological symptoms. Prophylactic or corrective 3α-DIOL treatment (4 mg/kg/2days) prevented or
suppressed PAC-evoked heat-thermal hyperalgesia, cold-allodynia and mechanical allodynia/hyperalgesia, by
reversing to normal, decreased thermal and mechanical pain thresholds of PAC-treated rats. Electrophysiological
studies demonstrated that 3α-DIOL restored control values of nerve conduction velocity and action potential peak
amplitude significantly altered by PAC-treatment. 3α-DIOL also repaired PAC-induced nerve damages by restoring
normal neurofilament-200 level in peripheral axons and control amount of 2’,3’-cyclic-nucleotide-3’-
phosphodiesterase in myelin sheaths. Decreased density of intraepidermal nerve fibers evoked by PAC-therapy was
also counteracted by 3α-DIOL treatment. More importantly, 3α-DIOL beneficial effects were not sedation-dependent
but resulted from its neuroprotective ability, nerve tissue repairing capacity and long-term analgesic action.
Altogether, our results showing that 3α-DIOL efficiently counteracted PAC-evoked painful symptoms, also offer
interesting possibilities to develop neurosteroid-based strategies against chemotherapy-induced peripheral
neuropathy. This article shows that the prophylactic or corrective treatment with 3α-androstanediol prevents or
suppresses PAC-evoked painful symptoms and peripheral nerve dysfunctions in rats. The data suggest that 3α-
androstanediol-based therapy may constitute an efficient strategy to explore in humans for the eradication of
chemotherapy-induced peripheral neuropathy.
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Introduction
Chemotherapy with antineoplastic drugs remains so far the
widely used and unavoidable treatment of several cancers.
However, the success of many cancer treatments is hampered
by antineoplastic-induced painful peripheral neuropathy and
neuropathological symptoms that constitute a major health
concern. Neuropathic pain, histopathological, neurochemical
and functional alterations of peripheral nerves evoked by
anticancer drugs represent a leading cause of discontinuation
of successful treatments [1,2]. These neuropathological
symptoms restrict therapeutic doses of antineoplastics to
suboptimal concentrations unable to kill tumor cells and
significantly affect the quality of life of millions of patients [3-5].
Painful neuropathological symptoms are generated by various
anticancer drugs including paclitaxel (also called taxol®) that is
widely used to treat breast cancer and several other
malignancies such as ovarian, lung, head and bladder cancers
and AIDS-related Kaposi’s sarcoma [6-11]. Paclitaxel is known
to induce sensory peripheral neuropathy with burning pain
symptoms, allodynia, hyperalgesia tingling and numbness
[1,3,12-18]. Several attempts have been made to treat or
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prevent antineoplastic-induced painful neuropathy with various
neuroprotective agents but the results are contradictory and
most of the compounds used were ineffective or induced
themselves adverse effects such as nausea, reflex
dysfunctions, treatment-emergent nervousness, insomnia,
tremor, anorexia or stomach burning [19-23]. Therefore, it is
crucial to identify novel drugs that may efficiently prevent or
suppress antineoplastic-induced painful and neuropathological
symptoms without evoking themselves undesirable action or
severe side-effects. In a recent study, we observed that
progesterone-derived 3α-5α-reduced metabolites exerted
potent neuroprotective effects against oxaliplatin- or vincristine-
induced peripheral neuropathy in rats, suggesting that 3α-5α-
neurosteroid-based strategies may offer serious opportunities
to develop effective therapies against anticancer drug-evoked
painful neuropathic symptoms [24,25]. Among the family of
3α-5α-neurosteroids are naturally-produced molecules such as
allopregnanolone and 3α-androstanediol (3α-DIOL) which
activate allosterically the GABAA receptor and potentiate the
central inhibition [26-34]. While allopregnanolone has
extensively been investigated in several experimental models
and in humans as a neuroprotective, neurogenic, anaesthetic,
anxiolytic or analgesic compound, the neurosteroid 3α-DIOL
has received little attention [26,35-42]. The present study was
therefore designed to investigate whether 3α-DIOL may also be
a neuroprotective neurosteroid offering effective possibilities for
the treatment of chemotherapy-induced painful neuropathy and
neuropathological symptoms. Thus, we assessed the potential
of 3α-DIOL to prevent or suppress paclitaxel-evoked
neurochemical and functional abnormalities in rat peripheral
nerves. In particular, we used a multidisciplinary approach to
determine the ability of 3α-DIOL to prevent or counteract
several neuropathological parameters evoked by paclitaxel
therapy such as behavioral painful symptoms (mechanical and
thermal allodynia or hyperalgesia), electrophysiological
deficiency (decreased nerve conduction velocity) and
histopathological alterations including the repression of
neurofilament 200 kDa (NF200) in peripheral nerve axons, the
decrease of intraepidermal nerve fiber (IENF) density in
intraplantar skin and the reduction of peripheral expression of
myelin enzyme 2’,3’-cyclic-nucleotide-3’-phosphodiesterase
(CNPase) that is pivotal for axonal survival [43,44].
Methods
Animals
Adult male Sprague-Dawley rats weighing 250-300 g were
used. The experiments were performed with male animals in
order to avoid eventual fluctuations of results that may happen
in females through the different phases of the oestral cycle
[45-47]. The animals were obtained from a commercial source
(Janvier, Le Genest St Isle, France) and housed under
standard laboratory conditions in a 14/10 h light/dark cycle with
food and water ad libitum. Animals were allowed a 1 week
acclimatization period before being used in experiments.
Ethic statement
Animal care and manipulations were performed according to
The European Community Council Directives (86/609/EC) and
under the supervision of authorized investigators. All
experiments were performed minimizing the number of animals
used and their suffering in accordance with the Alsace
Department of Veterinary Public Health Guide for the Care and
Use of Laboratory Animals. The ethics committee of the Alsace
Department of Veterinary Public Health Guide for the Care and
Use of Laboratory Animals specifically approved the protocol
used in the present study (Agreement number 67-186). The
experiments also followed the International Association for the
Study of Pain ethical guidelines [48].
Drugs and treatments
Paclitaxel (PAC; Sequoia Research Products Ltd, UK) was
dissolved in 10% Cremophor EL® in saline (Sigma-Aldrich, St
Louis, MO, USA), used as vehicle (VEHcrem) and stored at 4°C.
PAC was intraperitoneally (i.p.) injected every-2 days during 1
week, at a concentration of 1 mg/kg/injection depending on the
daily body weight [16]. The chemotherapy was therefore
performed at D1, D3, D5 and D7. Thus, the animals received a
total of 4 mg/kg of PAC. Control rats were injected with the
vehicle ‘10% Cremophor EL® in saline’ solution or VEHcrem (1
ml/kg) according to a similar schedule. Before the onset of PAC
(versus vehicle) treatment, behavioral tests were performed in
all rats in order to determine the pre-injection values of the
mechanical (Day 0 or D0), cold (D0) and heat thermal (Day 1
or D1) nociceptive thresholds. After PAC or vehicle treatment
onset, behavioral analyses were realized once a week to
assess alternately the mechanical or thermal sensitivity.
3α-androstanediol or 3α-DIOL (Steraloids, Newport, RI,
USA) was diluted in hydroxypropylcellulose or HPC 0.3%
(Sigma-Aldrich, St Louis, MO) in water used as vehicle
(VEHhpc). Consequently, it should be noted that 4 different
groups of control animals were used for the whole study: (i)
naive non-treated rats, (ii) (VEHcrem)-treated rats, (iii) (VEHhpc)-
treated rats and (iv) (VEHcrem + VEHhpc)-treated rats. 3α-DIOL
was i.p. administered immediately after the behavioral test
session. Two types of treatments were performed using 3α-
DIOL. Corrective 3α-DIOL treatment, which aimed at
suppressing painful neuropathic symptoms induced by the 1
week PAC treatment (administered at D1, D3, D5, and D7),
consisted in starting 3α-DIOL i.p. administration 8 days after
the end of PAC treatment (D15). Therapy with 3α-DIOL lasted
2 weeks (D15, D17, D19, D21, D23, D25 and D27).
Prophylactic 3α-DIOL treatment, which aimed at preventing the
development of PAC-induced neuropathic pain, consisted in
3α-DIOL administration before the onset and during the
treatment with PAC. Thus, for the prophylactic strategy (3α-
DIOL administration before PAC injections), 3α-DIOL was
administered at D1, D3, D5 and D7 before PAC treatment
started at D8. Then, PAC was injected at D8, D10, D12 and
D14 while 3α-DIOL treatment was continued at D9, D11, D13,
D15, D17, D19, D21, D23 and D25. Behavioral experiments,
electrophysiological studies, immunohistochemical
investigations, microscopic and cellular analyses were
performed to determine 3α-DIOL effects on PAC-induced
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painful symptoms as well as peripheral nerve alterations.
Experimenters were completely blind to the experimental
conditions of animals. Corrective and prophylactic effects of 3α-
DIOL against PAC-induced painful neuropathy were
investigated along the treatment period but also one week after
the end of 3α-DIOL administration.
Nociceptive behavioral tests
The mechanical nociceptive sensitivity threshold was
evaluated in individual rats placed on Plexiglas® boxes (30 x
30 x 25 cm) upon an elevated metal grid allowing access to the
plantar surface of the hind paws. The presence of mechanical
allodynia and hyperalgesia were assessed using a series of
calibrated von Frey hairs (1, 2, 4, 6, 8, 10, 15, 26g; Stoelting,
Wood Dale, IL), which were applied to the plantar surface of
the hind paw with increasing force until the individual filament
used just started to bend. The filament was applied for a period
of 1-2 s and the procedure was repeated five times at 4-5 s
intervals. The threshold for paw withdrawal was calculated by
taking the average of ten (five per paw) repeated stimuli (in g)
which induced a reflex paw withdrawal. Only robust and
immediate withdrawal responses followed by a licking of the
paw were considered as positive. Naive untreated rats never
withdraw from stimulations less than 6 g but respond 15-20%
of the time for 15 g stimulus and 35-40% for 26 g stimulus.
Observation of responses for stimulations < 6 g after drug
administrations is indicative of mechanical allodynia. Increased
level of responding for 15 and 26 g after treatment is indicative
of mechano-hyperalgesia. Decreased level of responding for
26 g after treatment is indicative of antinociceptive effect.
Heat thermal nociceptive sensitivity was assessed by using a
Plantar test apparatus (Ugo Basile, Comerio, Italy) which
measures the paw withdrawal latency in response to radiant
heat [49]. The rats were first allowed to habituate to the
apparatus for 10 min before testing. Each rat was placed
individually in clear Plexiglas® boxes (23 x 18 x 14 cm)
positioned on a clear plastic surface. The heat source was then
positioned under the plantar surface of the hind paw and
activated with an infra-red light beam. The heat source is
connected to a timer which automatically switched off the heat
when the paw was withdrawn. A cut-off time of 20 s was used
to prevent tissue damage in absence of response. Three
latencies were obtained alternately from each hind paw 5 min
apart. No consistent left and right differences were observed.
The mean paw withdrawal latency (in seconds) of hind paws
was determined from an average of six separate measures
(three per paw) at a given time point. Testing boxes were
thoroughly cleaned between each test session.
Cold thermal nociceptive sensitivity was assessed by using
the acetone test. Rats were placed on Plexiglas® boxes (30 x
30 x 25 cm) upon an elevated metal grid allowing access to the
plantar surface of the hind paws. Fifty microliters of acetone
(Sigma-Aldrich, St Louis, MO) was sprayed onto the plantar
skin of each hind paw 3 times with a Hamilton syringe. Rats
were observed 20 s from the start of the acetone spray. The
latency is measured for the withdrawal followed by a licking of
the hind paw. Normal rats ignore the stimulus or occasionally
respond with a very small withdrawal taking place lately without
licking the hind paw. Neuropathic animals respond with a rapid
and intense withdrawal followed by a licking of the hind paw.
Three latencies were obtained alternately from each hind
paw 5 min apart. No consistent left and right differences were
observed. The mean paw withdrawal latency (in seconds) of
hind paws was determined from an average of six separate
measures (three per paw) at a given time point. Testing boxes
were thoroughly cleaned between each test session.
Openfield test
The openfield (100x100x35 cm) has a 64-square grid floor
(8x8 squares, 12.5 cm/side) with an overhead light for
illumination. The number of squares entered and the number of
rears on the wall were used as indexes of horizontal and
vertical exploratory behavior, respectively. These numbers
were recorded during a five-minute test period.
Electrophysiological studies
Sciatic nerve action potential (NAP) recording was performed
as previously described [24,25]. Briefly, sciatic nerves were
rapidly dissected from decapitated rats under urethane
anesthesia (25%, 0.5 ml/100g) and immerged in saline medium
(NaCl 133, KCl 2, CaCl2 1, MgCl2 2, HEPES 10 and glucose 10
pH 7.4) 5 to 10 min before recording. The sciatic nerve was put
on chlorinated silver electrodes mounted in a classical
homemade electrodes holder chamber. Square-shaped
stimulating pulses of 0.1ms duration generated by Clampex
routine of the Pclamp software package (Axon Instruments,
CA, USA) were applied to the distal end of the nerve through
Digidata 1322A interface (Axon Instruments, CA, USA). Bipolar
sciatic nerve action potentials (NAP) were recorded at the
proximal end of the nerve (∆x=19 mm distance from the
stimulus point) using an ISO-DAM8A differential amplifier
(Word Precision Instruments, UK) with a bandwidth of 10 -
10,000 Hz. The signal was digitized (500 kHz) with the Digidata
1322A. Artifact of stimulation was obtained in isolation using a
double pulse protocol allowing the second stimulation to occur
in refractory period. This stimulus artifact was subtracted from
recorded NAPs before analysis with Pclamp software.
Nerve conduction velocity (CV) was calculated using the
latency between the beginning of stimulus artifact and the NAP
onset (∆tLatency) or the NAP peak (∆tPeak) for the fastest and
relatively slower fibers group respectively according to the
equations:
CVLatency = ∆x / ∆tLatency
CVPeak = ∆x / ∆tPeak
Data obtained from the different conditions were compared
using one way ANOVA statistical test followed by Bonferroni's
Multiple Comparison Test. Statistical significance was fixed as
usually at p<0.05.
Immunohistochemical studies
At the end of the last behavioral test session, sciatic nerves
and hind paw intra-plantar skins were removed to allow
immunohistochemical studies. Thus, animals were deeply
anesthetized with 25% urethane (0.5 ml/100g, i.p.) and
perfused transcardially with 100 ml of 0.1 M phosphate
buffered (PB; pH 7.4). The perfusion was carried out with 450
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ml of fixative solution (4% formaldehyde and 0.2% picric acid in
PB). Sciatic nerves and plantar skins were rapidly dissected
and postfixed in the same fixative solution for 24h. Afterwards,
the tissues were immersed in PB containing 15% sucrose for
24h and then transferred into 30% sucrose PB for 24h. Sciatic
nerves and intraplantar skins were then placed in embedding
medium (OCT, Tissue-Tek, Reichert-Jung, Nussloch,
Germany) and immediately frozen at -80°C. Sagittal sections
(10-µm thick) were cut in a cryostat HM 560 (Microm,
Francheville, France) and mounted on glass slides coated with
gelatin and chromium potassium sulfate. Tissue sections were
pre-incubated for 1 hour with 5% nonimmune donkey or goat
serum in PB containing 0.3% Triton X-100 (PBT). Afterwards,
the sciatic nerve sections were incubated overnight at 4°C with
a mouse monoclonal antibody against NF200 (Clone N52;
Sigma-Aldrich, St Louis, MO) diluted at 1:250 in PBT or a
mouse monoclonal antibody against 2’,3’-cyclic nucleotide 3’-
phosphodiesterase (CNPase; Sigma-Aldrich, St Louis, MO)
diluted at 1:100 in PBT. Hind paw intra-plantar skin sections
were incubated overnight at 4°C with the rabbit polyclonal
antibody against the protein gene product PGP9.5 (Cedarlane
Laboratories, Ontario, Canada) diluted at 1:500 in PBT. The
procedure was carried on by rinsing all of the tissue sections 3
times in PB (15 min/rinse) and transferring them for 2 hours
into Alexa-488-conjugated donkey anti-mouse or FITC-
conjugated goat anti-rabbit (Chemicon, Temecula, CA) diluted
at 1:300 in PBT. Finally, the sections were rinsed for 1 hour in
PB and mounted in Vectashield (Vector Laboratories,
Burlingame, CA). Although specificity of the antibodies has
previously been demonstrated [50-54], internal control
experiments were performed in the present work as follows: (i)
substitution of CNPase, NF200 or PGP9.5 antiserum with PBT,
(ii) replacement of CNPase, NF200 or PGP9.5 antibody by
non-immune mouse or rabbit serum and (iii) preincubation of
CNPase, NF200 or PGP9.5 antibody with purified CNPase,
NF200 or PGP9.5, respectively. The preparations were
examined under a multichannel confocal laser-scanning
microscope (Leica Confocal Systems, Paris, France) assisted
by a pentium IV PC (Leica Microsystems). The number of
CNPase or NF200 immunoreactive fibers was determined in a
counting square of 200 x 200 µm2 on sagittal sections of sciatic
nerves isolated from each experimental group. Quantification of
NF200 immunoreactivity was performed on sciatic nerve
sagittal sections by using ImageJ software. Results were
expressed as % of control (+ SEM). The number of PGP9.5
positive-intraepidermal nerve fibers (IENF) was quantified as
previously described [50,52]: all ascending nerve fibers that
cross into the epidermis were counted, no minimum length was
required and secondary branching into the epidermis was
excluded from quantification. IENF counts are expressed as
the number per mm of epidermal border. Experimenters were
completely blind to the experimental conditions of animals.
Statistical analyses
One or two-way repeated measures ANOVAs followed by
Newman-Keuls post hoc comparisons were used. The data
which did not exhibit a Gaussian distribution were analyzed by
the non-parametric Mann-Whitney U test. The statistical
significance of differences between sciatic nerve conduction
velocities or NAP amplitude peaks was assessed by one way
ANOVA statistical test followed by Bonferroni's Multiple
Comparison Test. Data were analyzed with Statistica Software
5.1 (Statsoft, Maisons-Alfort, France). A p-value of less than
0.05 was considered significant.
Results
Effects of PAC on the mechanical nociceptive
threshold
Before the onset of PAC or vehicle (Cremophor 10%)
treatment, the percentages of paw withdrawal for mechanical
stimulations were 0% for von Frey filaments < 6 g, 10-15% for
15 g and 35-40% for 26 g. In animals receiving the vehicle, the
percentages of withdrawal responses remained unchanged all
treatment days (Figure 1A-C). In contrast, from D15, paw
withdrawal responses in PAC-treated rats were observed
(3-26%; p<0.005) for von Frey filaments < 6 g (mechanical
allodynia) (Figure 1A) and increased levels of responding for
15g (30-71.5%; p<0.005) and for 26 g (60-87.5%; p<0.005)
were detected (mechano-hyperalgesia) (Figure 1B-C). PAC-
induced mechanical allodynia and hyperalgesia, which started
one week after the withdrawal of PAC treatment, persisted, at
least 3 weeks (Figure 1A-C).
Effects of PAC on cold thermal nociceptive sensitivity
Prior to PAC or vehicle (10% Cremophor in saline) treatment,
no paw withdrawal response was induced by acetone spray
during the whole observation period (20 s), indicating that
acetone-evoked cold stimulation is not noxious in naive rats. In
animals receiving the vehicle, the withdrawal latency remained
unchanged (no paw withdrawal response during 20 s) all
treatment days (Figure 1D). In contrast, the withdrawal latency
significantly decreased from 20 s to 15 s at D15 and to 10 s at
D29 (last time point recorded) in PAC-treated animals
(p<0.001), showing that PAC treatment caused cold thermal
allodynia in rats (Figure 1D).
Effects of PAC on heat thermal nociceptive sensitivity
The baseline withdrawal latency characterizing the heat
thermal pain threshold was around 11.5 ± 0.2 s on each paw of
naive rats before the treatment onset. No significant changes of
the thermal thresholds were observed in animal receiving the
vehicle (Figure 1E). In contrast, a significant decrease of the
heat thermal nociceptive threshold was observed in PAC-
treated rats (from 11.4 to 9.2 s) at D16 (p<0.05) and this
threshold remained significantly lower until D30 (p<0.001)
(Figure 1E).
Effects of PAC on sciatic nerve action potential and
conduction velocity
The sciatic NAP recorded in our conditions concern the
myelinated fibers that may essentially be Aδ fibers owing to
their conductance velocity range. As these fibers have different
diameters, a large bandwidth of CVs is generated. The higher
fiber CVs contribute to the NAP onset while the smallest CVs
Neuroprotective Effect of 3α-Androstanediol
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Figure 1.  Effect of PAC treatment on the rat mechanical (A-C) and thermal (D, E) nociceptive threshold.  (A-C) Time-course
of mechanical allodynia (A) and hyperalgesia (B,C) induced by PAC treatment. Graphs show the mean + SEM of the percentages of
paw withdrawal responses to mechanical stimulation by von Frey filament 4 g (A), 15 g (B) or 26 g (C) (n=8 per group). (D,E)
Effects of PAC treatment on rat cold (D) or heat (E) thermal nociceptive threshold assessed by acetone (D) or Plantar (E) tests.
Each point represents the mean + SEM of 6 observations in each of 8 rats. Non-parametric Mann-Whitney U test was used for the
analysis of the von Frey test results and one-way repeated measures ANOVAs followed by Newman-Keuls post hoc comparisons
were used for acetone and Plantar tests. Statistical differences between control and paclitaxel group on each testing day are shown.
* p<0.05, *** p<0.005.
doi: 10.1371/journal.pone.0080915.g001
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are involved in the NAP peak. Figure 2A illustrates mean traces
of sciatic NAPs recorded from vehicle- and PAC-treated rats.
PAC affected both NAP peak amplitude and conductance
velocity. In the case illustrated in Figure 2A, the CV of the
fastest fibers (NAP onset) was reduced by 41.4% under PAC
treatment (39.6 and 23.2 m/s for vehicle and PAC,
respectively) while the slowest fibers (peak of NAP) was
decreased about 33.6% (absolute values at NAP peak CV
were 13.3 and 8.8 m/s in vehicle and PAC treated rats,
respectively). Mean reduction values obtained for CVlatency and
CVpeak were 32.9 ± 0.7 and 24.7 ± 1.0%, respectively (Figure
2B). The NAP peak amplitude was greatly reduced and the
values for the NAP’s first phase in the case illustrated were 2.9
and 1.2 mV for vehicle- and PAC-treated rats, respectively,
giving a 58% inhibition of sciatic nerve function (Figure 2A).
Mean values obtained in each condition were 1.5 ± 0.2 and 0.7
± 0.1 mV respectively for vehicle- and PAC-treated rats,
indicating that the mean decrease of NAP peak amplitude
evoked by PAC was 54 ± 3% (Figure 2C).
Effects of PAC on NF200 expression in peripheral nerve
axons
To determine whether PAC treatment alters the structural
organization of peripheral axons, we used
immunohistochemical procedure to compare the expression of
the key neuronal cytoskeleton protein NF200 [55] in PAC-
treated and control rat sciatic nerve axons. Our results showed
an intense NF200-like immunoreactivity in several processes in
vehicle-treated or control rat sciatic nerves (Figure 3A). PAC-
treatment drastically decreased NF200-immunofluorescence in
sciatic nerve axons (Figure 3B). Quantitative analysis using the
counting score method combined with ImageJ software
Figure 2.  PAC effects on rat sciatic nerve action potential (NPA) peak amplitude and conduction velocity.  (A) Mean traces
of biphasic NAPs recorded from animals treated with vehicle (black curve) or PAC (grey curve). The nerve was stimulated with a
supra-maximal pulse potential (1 V) as indicated by the protocol trace (lower trace). The arrows 1-3 indicate the beginning of the
stimulation artifact (1) and the onset of NAP in control (2) and PAC (3) conditions giving a calculated NAP CVlatency in this case of
39.6 and 23.2 m/s for control and PAC, respectively. Note the reduction of NAP peak amplitude in PAC condition (1.2 mV versus 2.9
mV in controls). (B,C) NAP conduction velocity (B) and peak amplitude (C) histograms of statistical data obtained for vehicle- and
PAC-treated rats (n=8 for each condition). ** p<0.01, *** p<0.005.
doi: 10.1371/journal.pone.0080915.g002
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calculation revealed a 33% decrease of NF200-immunostaining
in PAC-treated sciatic nerve axons compared to controls
(p<0.001) (Figure 4A).
Effects of PAC on intraepidermal nerve fiber density in
intraplantar skin
Intraepidermal nerve fibers (IENF) were firstly
immunolabeled in rat hind paw intraplantar skin with a specific
antibody against PGP9.5 (Figure 3C,D). Then, IENF density
was quantified in vehicle- and PAC-treated rat hind paw intra-
plantar skins. PAC treatment decreased by 61% PGP9.5-
immunoreactivity or IENF density in intra-plantar epidermis
(p<0.001) (Figure 4B).
Effects of PAC on CNPase expression in sciatic nerves
As previous studies demonstrated that the non-compact
myelin protein CNPase, pivotal for axonal survival, is
dysregulated in experimental peripheral neuropathies
[24,43,44], we have determined the effects of PAC treatment
on CNPase expression in Schwann cells surrounding axonal
processes of the rat sciatic nerve. Intense immunoreactivity for
CNPase was visualized on sagittal sections of naive or vehicle-
treated rat sciatic nerves (Figure 3E). PAC-treatment
Figure 3.  Photomicrographs of sagittal sections of sciatic nerves (A,B,E,F) or hind paw intraplantar skins (C,D) dissected
from vehicle (A,C,E)- and PAC (B,D,F)-treated rats.  Nerve sections were labeled with the monoclonal NF200 antibody (A,B) or
with the monoclonal anti-CNPase (E,F) revealed with Alexa-488-conjugated donkey anti-mouse. (C,D) Intraplantar skin sections
were labeled with the polyclonal anti-PGP9.5 revealed with FITC-conjugated goat anti-rabbit. White arrows indicated intraepidermal
nerve fibers. Scale bar=50µm.
doi: 10.1371/journal.pone.0080915.g003
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significantly reduced the intensity of CNPase-immunostaining
in sciatic nerves (Figure 3F). Comparative analysis of the
numbers of CNPase-positive Schwann cell bodies detected in
counting squares (200 x 200 µm2) showed that PAC treatment
caused a drastic decrease (-44%) of CNPase expression in
sciatic nerves (p<0.001) (Figure 4C).
Figure 4.  Comparison of IENF density, NF-200 or CNPase expression in vehicle- and PAC-treated rat nerves.  (A)
Comparative analysis of NF200-immunostaining density (actual counts for NF200-positive fibers) detected in sciatic nerve sections
dissected from vehicle- and PAC-treated rats. (B) Comparative analysis of IENF density (counts for PGP9.5-positive terminals)
measured in vehicle- and PAC-treated rat intraplantar skin sections. (C) Comparative analysis of the numbers of CNPase-positive
Schwann cell bodies detected in sciatic nerve sections dissected from vehicle- and PAC-treated rats. Each value is expressed as
percent (+ SEM) of CNPase-positive cells bodies detected in sciatic nerve sections of control (vehicle-treated) rats. n=8 per group.
*** p<0.001.
doi: 10.1371/journal.pone.0080915.g004
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Action of 3α-androstanediol against PAC-induced cold
allodynia, heat hyperalgesia and mechanical allodynia
or hyperalgesia
Although previous dose-response studies have identified 1 to
4 mg/kg as an effective dose range for 3α-androstanediol
neuroactivity in vivo [29,32,56,57], we investigated in the
present work the dose- and injection frequency-dependent
effects of 3α-DIOL (by testing 2 or 4 mg/kg every 2 or 4 days)
on the mechanical nociceptive thresholds of vehicle- and PAC-
treated rats (Figure 5). In vehicle-treated animals, corrective
3α-DIOL treatments at 2 or 4 mg/kg every 2 days (Figure 5A)
or at 4 mg/kg every 4 days (Figure 5B) significantly decreased
the percent of responses to 26 g (p<0.05), indicating an
antinociceptive effect of 3α-DIOL. In PAC-treated animals, the
mechanical hyperalgesia (p<0.05) evoked by PAC was only
partially reduced by 3α-DIOL corrective treatment at the dose
of 2 mg/kg every 2 or 4 days or at 4 mg/kg every 4 days
(p<0.05; Figure 5). In contrast, at the dose of 4 mg/kg every 2
days, 3α-DIOL corrective treatment was capable to abolish
completely PAC-induced mechano-hyperalgesia and to restore
a normal mechanical sensitivity threshold in PAC-treated rats
(p<0.05; Figure 5A). Interestingly, we observed that the
prophylactic treatment with 3α-DIOL at the same dose (4
mg/kg/2 days) has also successfully prevented the occurrence
of PAC-evoked abnormal mechanical perception (Figure 6).
Consequently, 3α-DIOL at 4 mg/kg injected every 2 days
appeared as the best or optimal dose to be considered for the
elaboration of an effective corrective or prophylactic strategy
against PAC-induced neuropathic symptoms in rats. Indeed,
3α-DIOL (4 mg/kg/2 days), which increased the mechanical
and thermal pain thresholds (p<0.05), exerted a potent
antinociceptive action in control rats (Figure 6C,E,H,J). When
neuropathic pain symptoms are already installed in PAC-
treated rats, corrective 3α-DIOL treatment administered during
two weeks (7 injections of 3α-DIOL 4 mg/kg) totally abolished
the cold allodynia, heat hyperalgesia as well as the mechanical
allodynia and hyperalgesia (p<0.005) by restoring normal cold-
and heat-thermal and mechanical pain thresholds in PAC-
treated animals (Figure 6A-E). Prophylactic administration of
3α-DIOL (4 mg/kg every 2 days), which started 8 days before
PAC injections and was maintained during PAC treatment,
completely prevented PAC-induced cold allodynia, heat
hyperalgesia and mechanical allodynia or hyperalgesia
(p<0.005) (Figure 6F-J). Neuropathic pain symptoms did not
reappear in PAC-treated rats one week (D36 or D37) after the
end of 3α-DIOL corrective or prophylactic treatment (Figure 6).
To verify that the beneficial action of 3α-DIOL against PAC-
induced painful neuropathy is not due to a persistent sedative
effect causing weakness and reflex slowing, we have used the
openfield test to assess the motor capacity of control and PAC-
treated rats after 3α-DIOL corrective or prophylactic treatment.
As shown in Table 1, horizontal and vertical exploratory
behaviors were similar in all tested groups indicating that 3α-
DIOL corrective or prophylactic treatment did not reduce the rat
motor activity.
Effects of 3α-androstanediol against PAC-induced
peripheral nerve functional deficit
Treatment of naive rats with 3α-DIOL did not modify
peripheral nerve activity even though an increase tendency of
the mean values was observed in 3α-DIOL-treated rats
compared to vehicle treated animals (Figure 7). Most
importantly, 3α-DIOL reversed to normal values decreased
CVlatency, CVpeak and NAP peak amplitude induced by PAC
treatment (Figure 7A-C). CVlatency (34.1 ± 1.1 m/s), CVpeak (13.0
± 0.4 m/s) and NAP peak amplitude (1.5 ± 0.2 mV) mean
values of (PAC+3α-DIOL)-treated rats were similar to the
values of control animals (34.6 ± 0.6, 13.0 ± 0.4 m/s and 1.5 ±
0.1 mV, respectively).
Effects of 3α-androstanediol on PAC-induced NF200
repression in peripheral nerve axons
We observed that PAC treatment induced 30% decrease of
NF200-immunoreactivity in rat sciatic nerves (Figure 8A,B and
Figure 9A) (p<0.001). 3α-DIOL treatment administered during
two weeks totally reversed to normal decreased NF200
expression level induced by PAC in rat sciatic nerve axons
(p<0.001) (Figure 8A-D and Figure 9A).
Effects of 3α-androstanediol on PAC-induced loss of
intraepidermal nerve fibers
We detected 55% decrease of PGP9.5-immunoreactivity or
IENF density in hind paw intra-plantar skins of PAC-treated rats
compared to controls (p<0.001) (Figure 8E,F and Figure 9B).
3α-DIOL treatment during two weeks restored PGP9.5 or IENF
normal density in PAC-treated animals (p<0.001) (Figure 8E-H
and Figure 9B).
Effect of 3α-androstanediol on CNPase expression in
sciatic nerve
A strong increase of CNPase-immunoreactivity was
visualized in sciatic nerves of 3α-DIOL- compared to vehicle-
and PAC-treated rats (Figure 8I-L). In particular, counting of
CNPase-positive cells revealed that 3α-DIOL induced a 26%
increase (p<0.001) of CNPase expression in naive or healthy
rat sciatic nerves (Figure 9C). Interestingly, the 40% decrease
of CNPase-immunoreactivity evoked by PAC-treatment in rat
sciatic nerves was totally abolished by 3α-DIOL treatment
administered during two weeks (p<0.001) (Figure 8I-L and
Figure 9C).
Discussion
The present study revealed that a 7 day-treatment schedule
with PAC (1 mg/kg, daily body weight) induced painful
peripheral neuropathy and associated neurological symptoms
in rats. In particular, we observed that PAC treatment alters
functional, histological and neurochemical parameters of the rat
peripheral nerves as previously described in humans and
various other experimental models [1,3,12-18,58,59]. Indeed,
after one week treatment with PAC, the treated rats developed
physiological and functional abnormalities such as mechanical
allodynia and hyperalgesia, cold allodynia, heat-thermal
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hyperalgesia, nerve conduction velocity decrease and NAP
peak reduction. In addition, PAC also caused histopathological
and neurochemical alterations including the repression of
NF200 and CNPase in peripheral nerves and the decrease of
IENF density in paw intraplantar skin. It is well known that
NF200 is a constitutive protein of the cytoskeleton that pivotally
controls neuronal cell morphology and axoplasmatic transport.
Therefore, our results showing PAC-evoked NF200 repression
in sciatic nerves suggest that PAC treatment may generate
axonopathy in rats [1,3,60,61]. In agreement with this
suggestion, neurophysiological investigation and peripheral
nerve biopsy after docetaxel treatment in humans revealed an
axonal neuropathy with a preferentially loss of large myelinated
fibers [62]. Our studies also show that the natural neurosteroid
3α-DIOL is capable of preventing or correcting several major
neuropathological symptoms evoked by PAC treatment.
Figure 5.  Dose- and injection frequency-dependent effects of corrective 3α-DIOL treatment on the mechanical nociceptive
thresholds of control- and PAC-treated rats.  Corrective treatment every 2- (A) or 4-days (B) consisted in starting 3α-DIOL (2 or
4 mg/kg) or VEHhpc i.p. administrations 2 days after the end of PAC treatment. Threshold values represent responses to 26 g von
Frey filament (% ± SEM). Non-parametric Mann-Whitney U test was used. Statistical differences between controls and each
treatment group at each testing day are shown. n=6 per group; * p<0.05. * compared to VEHcrem+VEHhpc; # compared to PAC
+VEHhpc.
doi: 10.1371/journal.pone.0080915.g005
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Figure 6.  Effects of 3α-DIOL (4 mg/kg/2 days) corrective (A-E) or prophylactic (F-J) treatment on PAC-induced neuropathic
pain symptoms.  (A-C,F-H) Action of 3α-DIOL against PAC-induced mechanical allodynia (A,F) and hyperalgesia (B,C,G,H).
Chartbars show the mean + SEM of the percentages of paw withdrawal responses to mechanical stimulation by von Frey filament 4
g (A,F), 15 g (B,G) or 26 g (C,H) (n=8 per group). (D,I) Effect of 3α-DIOL against PAC-evoked cold-allodynia. (E,J) 3α-DIOL effects
on the heat thermal nociceptive thresholds of vehicle- and PAC-treated rats. Each bar represents the mean + SEM of 6
observations in each of 8 rats. Non-parametric Mann-Whitney U test was used for the analysis of the von Frey test results and two-
way repeated measures ANOVAs followed by Newman-Keuls post hoc comparisons were used for acetone and Plantar Tests.
Statistical differences between controls and each treatment group at each testing day are shown. * p<0.05, ** p<0.01, *** p<0.005. *
vs (VEHcrem + VEHhpc), # vs (PAC + VEHhpc).
doi: 10.1371/journal.pone.0080915.g006
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Indeed, our behavioral analyses demonstrated that
prophylactic or corrective 3α-DIOL treatment prevented or
suppressed PAC-induced neuropathic pain symptoms including
cold allodynia, heat-thermal hyperalgesia and mechanical
allodynia and hyperalgesia. Interestingly, our histopathological
and neurochemical studies demonstrated that 3α-DIOL
reversed to normal the repressed NF200 level observed in
PAC-treated rat peripheral nerve axons, suggesting that 3α-
DIOL-based therapy may be effective for the treatment of
antineoplastic-evoked axonopathy and/or neuronopathy.
Furthermore, our work revealed that 3α-DIOL prevented or
counteracted PAC-induced PGP9.5-like immunoreactivity and
IENF density decrease in intraplantar skin. Because epidermal
innervation loss constitutes a neuropathological damage
frequently occurring in antineoplastic-treated patients [1,52,63],
3α-DIOL appears as a promising neuroprotective compound
against toxic drug-induced alterations of epidermal
innervations.
It is well demonstrated that painful neurological symptoms
such as allodynia and hyperalgesia evoked by anticancer drugs
are generally associated with decreased peripheral nerve
Table 1. Effect of 3α-DIOL treatment (4 mg/kg/every 2
days) on the exploratory behaviors of control- and PAC-
treated rats.
3α-DIOL TreatmentGroup
Total number of
squares entered
Total number of
rears on the wall
Corrective VEHcrem+VEHhpc 327.25 ± 6.41 32 ± 1.22
 VEHcrem+3α-DIOL 320.5 ± 5.55 30.25 ± 1.70
  ns1 ns1
 PAC+VEHhpc 317.5 ± 9.51 31.5 ± 1.66
  ns1 ns1
 PAC+3α-DIOL 313 ± 8.18 30.5 ± 0.87
  ns1,2 ns1,2
Prophylactic VEHcrem+VEHhpc 308 ±13.28 29.75 ± 1.11
 VEHcrem+3α-DIOL 305.75 ± 7.87 30.75 ± 2.66
  ns1 ns1
 PAC+VEHhpc 295.75 ± 15.44 31.25 ± 1.65
  ns1 ns1
 PAC+3α-DIOL 293 ± 6.31 31 ± 1.58
  ns1,2 ns1,2
Total numbers of squares entered (± SEM) and of rears on the wall (± SEM)
indicated in the table are representative of horizontal and vertical exploratory
behaviors in the openfield test. For the corrective 3α-DIOL treatment schedule,
PAC or VEHcrem was injected at D1, D3, D5 and D7; 3α-DIOL or VEHhpc i.p.
administrations started 8 days after the end of PAC treatment. For the prophylactic
treatment schedule, 3α-DIOL or VEHhpc i.p. was administered every 2 days from
D1 while PAC or VEHcrem treatment, which started from D9, was administered at
D9, D11, D13 and D15. Testing was performed at D28, i.e. 1 day after the 7th 3α-
DIOL injection in the corrective treatment schedule or 3 days after the 13th 3α-
DIOL injection in the prophylactic treatment schedule n=4 per group; ns1, not
significant compared to VEHcrem+VEHhpc; ns2, not significant compared to PAC
+VEHhpc. VEH, vehicle; 3α-DIOL, 3α-androstanediol; PAC, paclitaxel.
doi: 10.1371/journal.pone.0080915.t001
conduction velocity and ectopic discharges [4,13,17,60,64-66].
Consistently, our electrophysiological and behavioral
investigations clearly evidenced a significant CVlatency reduction,
NAP peak amplitude decrease and a marked allodynia and
hyperalgesia in PAC-treated rats. Interestingly, 3α-DIOL was
also capable of rescuing PAC-treated rats from these
electrophysiological and functional alterations evoked by PAC
treatment. Moreover, in NF knock-out mice, decreased NAP
peak amplitude has been evidenced together with internodal
conductance changes that are known to be responsible for
nerve conduction block and CV reduction [67]. Low NF
expression levels, which are major intrinsic determinants of
axon caliber in large fibers, led to axonal diameter reduction
and subsequently to CV slowing [67-70]. In perfect accordance
with these data, our findings showed a drastic reduction of NF
expression level in PAC-treated rat peripheral nerves that was
correlated to a significant decrease of large fiber CV and NAP
peak amplitude. Therefore, the neuroprotective effect of 3α-
DIOL against PAC-induced painful neuropathological
symptoms appears to be dependent on its ability to reverse to
normal values decreased NF expression level, reduced CVlatency
and NAP peak amplitude in PAC-treated rat peripheral nerves.
Moreover, our results also revealed that 3α-DIOL modulate
differentially the expression of CNPase, NF200 and PGP9.5
genes. Indeed, in naive or vehicle-treated rats, 3α-DIOL
increased CNPase expression level in peripheral nerves but
did not modify the amounts of NF200 and PGP9.5.
Interestingly, under neuropathological situations when NF200,
PGP9.5 and CNPase levels were repressed by PAC treatment,
3α-DIOL was able to restore to normal the levels of all of these
3 key proteins controlling peripheral nerve activities and
intraepidermal innervation sensory functions. Altogether, these
results suggest that CNPase gene expression may be highly
sensitive to 3α-DIOL-evoked intracellular signaling while the
sensitivity of NF200 and PGP9.5 genes to 3α-DIOL may
increase only under pathophysiological situations thanks to the
activation of various transcription factors evoked by PAC
treatment [71-73]. Also, 3α-DIOL is known to stimulate the
central inhibitory system via the GABAA receptor, suggesting
that 3α-DIOL may exert an analgesic action which may
contribute to suppress PAC-evoked painful symptoms
[26-31,46]. Another important point is the fact that 3α-DIOL
may be inter-converted into 5α-DHT by the enzyme 3α-
hydroxysteroid oxido-reductase abundantly expressed in the
nervous system [39,74,75]. Therefore, the treatment with
exogenous 3α-DIOL may generate substantial endogenous
concentrations of 3α-DIOL and 5α-DHT which can exert both
neuroprotective and analgesic effects by activating GABAA
receptors and androgen nuclear receptors, respectively
[27-29,31,32,34,46,76]. The genomic mechanisms activated by
3α-DIOL treatment (via its metabolite 5α-DHT) may explain 3α-
DIOL ability to restore to normal values the decreased
CNPase, NF200 and PGP9.5 expression levels evoked by
PAC treatment in rat peripheral nerves. In support of this
hypothesis, it has been shown that androgens, acting via their
nuclear receptors, promote NF expression and neuritic process
development in peripheral nerves [77]. Furthermore, it has also
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been demonstrated that, in rodents, androgens promote the
expression of myelin proteins including CNPase level [78].
The beneficial effects exerted by 3α-DIOL against thermal
and mechanical allodynic and hyperalgesic symptoms may
result from the direct interactions of 3α-DIOL with GABAA
receptors inducing therefore and acute analgesia. However,
several indications provided by the present study show that the
beneficial action of 3α-DIOL against PAC-evoked painful
neuropathy does not depend on 3α-DIOL-induced sedation or
is not only the consequence of 3α-DIOL-evoked acute
analgesia but results from the combination of 3α-DIOL
neuroprotective ability, nerve tissue repairing capacity and long
Figure 7.  Curative effects of 3α-DIOL against PAC-induced reduction of sciatic nerve action potential parameters (CVlatency:
A; CVpeak: B and peak amplitude: C).  Histograms of normalized CVlatency and CVpeak show their reduction by PAC and recovery by
3α-DIOL treatment (A,B). Mean CV values were calculated as % of the mean CV obtained from vehicle-treated rats. (C) Recovery
from PAC-induced NAP peak amplitude decrease by 3α-DIOL treatment. Each value is the mean (+SEM) of NAP peak amplitude
obtained from 8 rat sciatic nerves per each group investigated. ** p<0.01, *** p<0.005. * vs (VEHcrem + VEHhpc), # vs (PAC + VEHhpc).
doi: 10.1371/journal.pone.0080915.g007
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term analgesic property. Indeed, we observed that prophylactic
3α-DIOL treatment prevented neurochemical and functional
alterations of peripheral nerves and IENF in PAC-treated rats
and these animals did not exhibit painful neuropathological
symptoms several days after the end of 3α-DIOL preventive
administration. In addition, one week after withdrawal of 3α-
DIOL corrective treatment, painful neurological symptoms did
not reappear in PAC-treated rats. Finally, our openfield
investigations revealed that the exploratory behavior and motor
activity were similar in control and PAC-treated rats after 3α-
DIOL preventive or corrective treatment, indicating that 3α-
DIOL beneficial effects against PAC-evoked painful peripheral
neuropathy and neurological symptoms did not result from its
sedative action.
In conclusion, the present study, which shows that the
neuroprotective neurosteroid 3α-DIOL effectively prevents and
suppresses several painful and neuropathological symptoms
evoked by PAC, also offers interesting opportunities for the
development neurosteroid-based therapies against
chemotherapy-induced peripheral neuropathy and painful
neurological disorders.
Figure 8.  Photomicrographs of sagittal sections of sciatic nerves (A-D,I-L) or intraplantar skins (E-H) dissected from
(VEHcrem + VEHhpc)(A,E,I)-, (PAC + VEHhpc)(B,F,J)-, (VEHcrem + 3α-DIOL)(C,G,K)- or (PAC + 3α-DIOL)(D,H,L)-treated rats.  Nerve
sections were labeled with the monoclonal NF200 antibody (A-D) or with the monoclonal anti-CNPase (I-L) revealed with
Alexa-488-conjugated donkey anti-mouse. (E-H) Intraplantar skin sections were labeled with the polyclonal anti-PGP9.5 revealed
with FITC-conjugated goat anti-rabbit. White arrows indicated intraepidermal nerve fibers. Scale bar, 50 µm.
doi: 10.1371/journal.pone.0080915.g008
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Figure 9.  Neuroprotective effects of 3α-DIOL corrective treatment against PAC-induced alterations in sciatic nerves and
intraplantar skin.  (A-C) Chartbars show NF200 (A) or CNPase (C) expression level in sciatic nerve sections or IENF density in
intraplantar skin sections (B) dissected from (VEHcrem + VEHhpc)-, (PAC + VEHhpc)-, (VEHcrem + 3α-DIOL)- and (PAC + 3α-DIOL)-
treated rats. (A) Each value is expressed as mean (+ SEM) of actual counts for NF200-positive fibers detected in sciatic nerve
sections. (B) Each value is expressed as mean (+ SEM) of IENF density (counts for PGP9.5-positive terminals) detected in
intraplantar skin sections. (C) Each value is expressed as percent (+ SEM) of CNPase-positive cells bodies detected in sciatic nerve
sections of control (VEHcrem + VEHhpc)-treated rats. n=8 per group. *** p<0.001 vs (VEHcrem + VEHhpc), ### p<0.001 vs (PAC +
VEHhpc).
doi: 10.1371/journal.pone.0080915.g009
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